Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | New therapies for MPNs: an update before ASH

Claire Harrison • 15 Nov 2019
MPN Advances Day 2019
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases CPI-0610 Fedratinib IMG-7289 Luspatercept Momelotinib Navitoclax Pacritinib Ropeginterferon alfa-2b Ruxolitinib
MAJIC

Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, highlights the range of new therapies for myeloproliferative neoplasms (MPNs) and what they can offer. This includes JAK, LSD1 and MDM2 inhibitors, among other strategies. This interview took place at the MPN Advances Day 2019 in London, UK.

More from Claire Harrison

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
1:58
The value of novel JAK2 and CALR-targeted therapies in MPNs
Claire Harrison • 24 Apr 2023
1:39
The role of transplantation in MPNs & factors to consider when selecting patients for transplant
Claire Harrison • 24 Apr 2023
2:33
Optimizing current treatment approaches in myelofibrosis
Claire Harrison • 24 Apr 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals